ArticleFrontiers in immunology2026
Immune biomarker landscape and fusion partner-phenotype associations in thoracic and head-and-neck NUT carcinoma.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thoracic and head and neck NUT carcinoma is a rare, highly aggressive NUTM1-rearranged malignancy with substantial diagnostic difficulty, marked phenotypic heterogeneity, and no established biomarker framework for immunotherapy stratification. Although fusion partners may contribute to clinicopathologic diversity, their relationship to phenotype and immune biomarkers remains insufficiently defined. Materials and methods: We performed an integrated literature-based analysis of thoracic and head and neck NUT carcinoma using English-language publications indexed in the Web of Science Core Collection from 1991 to 2025. Eligible studies were screened for clinicopathologic, fusion, and immune-biomarker data. Case-level variables were harmonized into anatomic and lineage-based strata to evaluate associations between fusion partners, phenotype, and immune features. PD-L1 status was harmonized into three descriptive categories based on author interpretation and/or reported TPS/CPS thresholds, and a binary sensitivity framework, Negative versus Any expression, was additionally applied to reduce the impact of heterogeneous assays and scoring systems. MSI and TMB were also extracted when available. Associations were assessed using two-sided Fisher's exact test with odds ratios and 95% confidence intervals. To strengthen the robustness and translational relevance of the findings, we additionally analyzed an independent retrospective institutional cohort of thoracic and head and neck NUT carcinoma. Results: The integrated clinicopathologic dataset included 229 thoracic/head and neck cases with definitive fusion annotations from 109 studies. Squamous lineage predominated (71.62%), but non-squamous and mixed phenotypes were also identified. Conclusion: This study defines the immune biomarker landscape of thoracic and head and neck NUT carcinoma within a clinicopathologic and fusion-partner framework. The predominance of PD-L1 negativity together with MSS/low-TMB features suggests a generally immunologically "cold" phenotype in most reported tumors, while exploratory fusion partner-specific enrichment patterns may help refine diagnostic suspicion and generate hypotheses for future biomarker-guided stratification. These findings provide a translational basis for rare-cancer immunobiology research and for the rational design of biomarker-integrated prospective studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.